Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with CLL (chronic lymphocytic leukemia) or SLL (small lymphocytic lymphoma) that doctors have determined needs treatment, based on established medical guidelines
- People who are at least 18 years old
- People whose cancer has at least one of the following high-risk features: a missing section of chromosome 17 (17p-deletion), a change in the TP53 gene, a complex set of chromosome abnormalities (3 or more changes across at least 2 cells), or a specific gene pattern called "unmutated IGHV status"
- People with a life expectancy of at least six months
- People whose bone marrow is producing enough platelets (a blood cell count above a certain level, as confirmed by a blood test)
- People whose kidneys are functioning at an adequate level (confirm with trial site for specific threshold)
- People whose liver is functioning at an adequate level, based on blood test results — unless any abnormality is directly caused by their CLL or a condition called Gilbert's Syndrome
- People who test negative for hepatitis B and hepatitis C, or who meet specific monitoring conditions if certain hepatitis markers are present (confirm with trial site for full details)
- People with a general health and activity level rated 0, 1, or 2 on a standard medical scale, meaning they are fully active to capable of limited self-care
Who may not be able to join:
- People who have previously received any treatment specifically targeting their CLL (with a limited exception for short-term corticosteroid use at low doses in the 10 days before starting the study)
- People whose CLL does not include any of the high-risk features listed above (17p-deletion, TP53 mutation, or complex chromosome abnormalities)
- People with serious problems affecting a major organ or body system — for example, advanced heart disease — that could make it unsafe to receive the study treatments or affect how the body absorbs the medications (including people who are unable to swallow tablets)
- People whose CLL has transformed into a more aggressive type of cancer (known as Richter transformation)
- People who currently have another type of cancer that requires systemic treatment
- People with an uncontrolled or active HIV infection, a condition called PML, or any other active serious infection
- People currently taking blood-thinning medications called warfarin or phenprocoumon
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne
Phone: +4922147888220
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.